Literature DB >> 32961248

Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.

Shuyun Dong1, Sundharraman Subramanian2, Kristin N Parent2, Mingnan Chen3.   

Abstract

Vaccines that induce cytotoxic T lymphocyte (CTL)-mediated immune responses constitute an important class of medical tools to fend off diseases like infections and malignancy. Epitope peptides, as a format of CTL vaccines, are being tested preclinically and clinically. To elicit CTL responses, epitope vaccines go through an epitope presentation pathway in dendritic cells (DCs) that has multiple bottleneck steps and hence is inefficient. Here, we report the development of a strategy to overcome one of these barriers, phagolysosomal escape in DCs. First, we furnished a previously established carrier-an immune-tolerant elastin-like polypeptide nanoparticle (iTEP NP)-with the peptides that are derived from the DNA polymerase of herpes simplex virus 1 (Pol peptides). Pol peptides were reported to facilitate phagolysosomal escape. In this study, while we found that Pol peptides promoted the CTL epitope presentation; we also discovered Pol peptides disrupted the formation of the iTEP NP. Thus, we engineered a series of new iTEPs and identified several iTEPs that could accommodate Pol peptides and maintain their NP structure at the same time. We next optimized one of these NPs so that its stability is responsive to its redox environment. This environment-responsive NP further strengthened the CTL epitope presentation and CTL responses. Lastly, we revealed how this NP and Pol peptides utilized biological cues of phagolysosomes to realize phagolysosomal escape and epitope release. In summary, we developed iTEP NP carriers with a new phagolysosomal escape function. These carriers, with their priorly incorporated functions, resolve three bottleneck issues in the CTL epitope presentation pathway: vaccine uptake, phagolysosomal escape, and epitope release.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxic T lymphocyte vaccine; Dendritic cells; Epitope; MHC class I; Nanoparticle; Phagolysosomal escapes; Polypeptide materials; Redox environment-responsive; Self-assembly; Vaccine carrier

Mesh:

Substances:

Year:  2020        PMID: 32961248      PMCID: PMC8729261          DOI: 10.1016/j.jconrel.2020.09.033

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  48 in total

Review 1.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

2.  Normal alveolar epithelial lining fluid contains high levels of glutathione.

Authors:  A M Cantin; S L North; R C Hubbard; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1987-07

Review 3.  CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Authors:  Jianda Yuan; Brian Ginsberg; David Page; Yanyun Li; Teresa Rasalan; Humilidad F Gallardo; Yinyan Xu; Sylvia Adams; Nina Bhardwaj; Klaus Busam; Lloyd J Old; James P Allison; Achim Jungbluth; Jedd D Wolchok
Journal:  Cancer Immunol Immunother       Date:  2011-04-05       Impact factor: 6.968

4.  Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.

Authors:  Shuyun Dong; Tiefeng Xu; Peng Wang; Peng Zhao; Mingnan Chen
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150

Review 5.  Compartmentation of glutathione: implications for the study of toxicity and disease.

Authors:  C V Smith; D P Jones; T M Guenthner; L H Lash; B H Lauterburg
Journal:  Toxicol Appl Pharmacol       Date:  1996-09       Impact factor: 4.219

Review 6.  Materials based tumor immunotherapy vaccines.

Authors:  Weiwei Aileen Li; David J Mooney
Journal:  Curr Opin Immunol       Date:  2013-01-18       Impact factor: 7.486

Review 7.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

8.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

9.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin.

Authors:  A Loregian; E Papini; B Satin; H S Marsden; T R Hirst; G Palù
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.